Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Conivaptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 known ✓ | P30518 | 16/20 | 1.00 |
| ▸ | AVPR1A known ✓ | P37288 | 13/20 | 1.00 |
| ▸ | OXTR | P30559 | 1/20 | 0.59 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Conivaptan SCHEMBL28043077 | 0.99 | AVPR2 (0.98) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL1649913 | 0.98 | AVPR2 (0.97) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL4625101 | 0.86 | AVPR2 (0.75) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL29406590 | 0.86 | AVPR2 (0.75) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL387232 | 0.85 | AVPR2 (0.74) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL8204092 | 0.85 | AVPR2 (0.74) | AVPR2AVPR1AOXTRAVPR1B | |
| Hydrochloric Acid SCHEMBL6993733 | 0.84 | AVPR2 (0.73) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6991859 | 0.84 | AVPR1A (0.72) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL17471526 | 0.83 | AVPR2 (0.72) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL11929158 | 0.83 | AVPR1A (0.71) | AVPR2AVPR1AOXTRAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3324 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12564590-B2 | Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof | SYNDAX PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-12533358-B1 | Methods of treatment with elinzanetant | BAYER CONSUMER CARE AG (CH) | 2026-01-27 | — | — | US | claimed |
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMALN CORP (US) | 2026-01-15 | — | — | US | claimed |
| EP-4637824-A1 | METHOD OF PREVENTING AND TREATING ALZHEIMER'S DISEASE AND RELATED DEMENTIAS WITH DRUGS INHIBITING THE INTERACTION BETWEEN 14-3-3G PROTEIN AND HEXOKINASE-1 PROTEIN | BIOVENTURES, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-12428475-B2 | Humanized anti-ACTH antibodies and use thereof | H. LUNDBECK A/S (DK) | 2025-09-30 | — | — | US | claimed |
| US-20020128259-A1 | Treatment of pulmonary hypertension | ASTELLAS IRELAND CO., LTD. (IE) | 2002-09-12 | — | — | US | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| EP-1195166-A2 | Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension | WARNER-LAMBERT COMPANY (US) | 2002-04-10 | — | — | EP | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| US-20020022054-A1 | Drug delivery system for averting pharmacokinetic drug interaction and method thereof | ASTELLAS IRELAND CO., LTD. (IE) | 2002-02-21 | — | — | US | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| WO-2001082920-A2 | TREATMENT OF CONGESTIVE HEART FAILURE WITH A COMPOSITION COMPRISING A DIURETIC AGENT AND A VASOPRESSIN ANTAGONIST | WARNER-LAMBERT COMPANY (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001054698-A1 | METHOD FOR PREVENTING OR TREATING POSTOPERATIVE ILEUS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2001054677-A2 | ACE INHIBITOR-VASOPRESSIN ANTAGONIST COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |